New OTC Division

Discussion in 'Galderma' started by Anonymous, May 12, 2015 at 8:17 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Overheard that a new OTC division to start soon with a sales contract force, any confirmation of this?
     

  2. Anonymous

    Anonymous Guest

    What are the products?? We already sell Cetaphil.
     
  3. Anonymous

    Anonymous Guest

    Not OTC but Consumer BU. Cetaphil and a few more products will be separated from the SM BU. in fact I have heard that it will be a separate affiliate and team reports to Switzerland directly.
     
  4. Anonymous

    Anonymous Guest

    Yes it sounds like it will be Cetaphil products and Galderma and Theracitix divisions will be strictly RX products. In my opinion it makes total sense.
     
  5. Anonymous

    Anonymous Guest

    I agree it does make total sense. However, it also draws in a bit of concern with the long term prospects of the Rx divisions. We are launching a few products that had been in the pipeline and in development. But it is clear that we are moving more to an aesthetic and consumer company which is more in Nestle's wheel house. Makes one wonder what are the long term prospects of the Rx BU.
     
  6. Anonymous

    Anonymous Guest

    Do not worry about the Rx division. They are the crown jewel of Nestle as they are a cash cow. The consumer division makes pennies on the dollar and the A&C is struggling to find an identity. Just look at our financials and you will see the same.
     
  7. Anonymous

    Anonymous Guest

    agree, we have great consumer brands that are floundering. No competitive point of difference, every one claims dermatologist recommended---
     
  8. Anonymous

    Anonymous Guest

    agree and what marketing idiot thinks Cetaphil is a BEAUTY brand. Our advertising just sucks.
     
  9. Anonymous

    Anonymous Guest

    I do not totally agree. Once the patent's expire on the Rx brands this place will be a consumer OTC and hopefully an aesthetic company. I do agree that the Aesthetic BU is floundering. But if you look at the facts the long term prospects and lack of pipeline will at some point put an end to the Rx side of the business. They waited so long to launch some of the Rx products that we only have less than three years of patent life left on some of them. So do the math and enjoy the ride until it comes to a stop.
     
  10. Anonymous

    Anonymous Guest

    And you really think Nestle will just let the Rx side die a slow death? You obviously do not understand what Business Development and R&D mean to a pharma company. Don't want people like you around so its best you probably leave, why wait for the end if you are so sure you know the ending already? good riddance.
     
  11. Anonymous

    Anonymous Guest

    thanks tracey and george good ole boys club in affect , still partying like its 1999
     
  12. Anonymous

    Anonymous Guest

    Well you are ignoring the history of this place my friend. They invested about 10% or more into R and D over the last 25 years. It might be higher if you take out the regulatory costs and all they have developed is Differin and Epiduo ( one new chemical entity in 30 years) everything else came out of acquisitions. Rx products and pipeline is drying up and the one poster who said some of the exclusivity is only 3 years such as the Ivermectin product is spot on. Keep drinking the Koolaid but they are already positioning the place for the long term aesthetics and OTC. Facts are facts.
     
  13. anonymous

    anonymous Guest

    hope they do this quickly. We've got a great otc portfolio that's completely under leveraged. Any Consumer marketers out there that can help? We are really weak!
     
  14. anonymous

    anonymous Guest

    Any news on this division. Do people like it. Are they having success?
     
  15. anonymous

    anonymous Guest

    It's interesting to read back
     
  16. anonymous

    anonymous Guest

    It's unfortunate but the leadership in charge of this division made questionable decisions in the beginning. middle and end of the active promotion period. By some appearances, based on erroneous decision making, it could be assumed that the failure of the sales force was intentionally orchestrated to dissolve the contract sales force. Galderma had the right to either continue the contract, bring over the Inventiv sales force or dissolve the division altogether. There is no question or argument that G could make whichever decision was best for the organization. "That's business". The manner and execution of the decision however, speaks volumes to the moral fiber of the leadership of the OTC division.
     
  17. anonymous

    anonymous Guest

    Yes the unethical and immoral ways they behave is one thing. Business is business, but is it smart business? To risk disrupting cetaphils momentum? MH made those decisions, now pres, hired new clueless impulsive Natzi egotistic leaders.... whom continue to disrupt the center of this business. is that smart business?
     
  18. anonymous

    anonymous Guest

    i.e., class-action lawsuit
    Re: Cet eczema calming lotion
    In truthinadvertising

    whose head will roll for this one... or should I say, who will be the sacrificial lamb ha!